Marstacimab, sold under the brand name Hympavzi, is a monoclonal antibody medication used for the treatment of hemophilia A and hemophilia B. It is a...
13 KB (1,005 words) - 04:47, 24 June 2025
B02BX08 Avatrombopag B02BX09 Fostamatinib B02BX10 Concizumab B02BX11 Marstacimab "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis"...
2 KB (311 words) - 15:18, 29 January 2025
(INN) maropitant citrate (USAN) maroxepin (INN) Marplan maslimomab (INN) marstacimab (INN) masoprocol (INN) Masterone (Syntex) Matulane matuzumab (INN) mavacoxib...
4 KB (270 words) - 04:44, 24 November 2024
2024. Retrieved 11 October 2024. "U.S. FDA Approves Pfizer's Hympavzi (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or...
146 KB (4,464 words) - 06:26, 24 June 2025
systemic Batroxobin Carbazochrome Concizumab Etamsylate Fostamatinib Marstacimab thrombopoietin receptor agonist Romiplostim Avatrombopag Eltrombopag...
9 KB (973 words) - 21:03, 29 May 2025
3/22/2016 subcutaneous humanized IL17A Plaque psoriasis 125521 Link marstacimab Hympavzi Pfizer 10/11/2024 intravenous fully human Tissue factor pathway...
61 KB (4,217 words) - 12:03, 27 June 2025